BiotechTube
Home/Pipeline/Ciltacabtagene Autoleucel (cilta-cel)

Ciltacabtagene Autoleucel (cilta-cel)

Relapsed/Refractory Multiple Myeloma

Approved / Phase 3ActiveCARTITUDE-4, CARTITUDE-5

Key Facts

Indication
Relapsed/Refractory Multiple Myeloma
Phase
Approved / Phase 3
Status
Active
Company
Legend Biotech

About Legend Biotech

Legend Biotech's mission is to discover, develop, and commercialize transformative cell therapies for patients with life-threatening diseases, primarily in oncology. Its core achievement is the successful global launch of CARVYKTI® (cilta-cel), a best-in-class CAR-T therapy for multiple myeloma, which has propelled the company to commercial leadership and validated its technology platform. The company's strategy centers on deepening its commercial footprint, advancing a broad pipeline of next-generation cell therapies, and expanding its manufacturing capabilities, all underpinned by a strategic global collaboration with Janssen (Johnson & Johnson).

View full company profile

Therapeutic Areas

OncologyHematology

Other Relapsed/Refractory Multiple Myeloma Drugs

DrugCompanyPhase
Aplidin (plitidepsin)PharmaMarApproved (Conditional - AU)
TECVAYLI + DARZALEX FASPROjohnson-and-johnson-innovative-medicineApproved
LinvoseltamabRegeneronPhase 3
Blenrep (belantamab mafodotin)GSKPhase III
CAR T-Cell Therapy ProgramDr. Reddy's LaboratoriesDevelopment
HDP-101Heidelberg PharmaPhase I/IIa
inobrodib + Pd (InoPd)CellCentricPhase 1/2
CT053CARsgen TherapeuticsPhase Ib/II
CT059CARsgen TherapeuticsPhase I
P-BCMA-ALLO1Poseida TherapeuticsPhase 1
P-BCMA-101Poseida TherapeuticsPhase 1/2
ABBV-383AbbViePhase 1